Patent intelligence · US
US 11999773
Anti-BCMA chimeric antigen receptors
Anti-BCMA chimeric antigen receptors
Patent details — US 11999773
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 4, 2024
- Expiration
- May 30, 2044
- Applicant
- Cartesian Therapeutics, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00
Quick answer
US 11999773 (Anti-BCMA chimeric antigen receptors) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Jun 4, 2024. Expires May 30, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cartesian Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00, A61K39/3955, A61K39/39558
More from Cartesian Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11999773?
US 11999773 (Anti-BCMA chimeric antigen receptors) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Jun 4, 2024. Expires May 30, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11999773?
Cartesian Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11999773 expire?
Our index shows an expiration date of May 30, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.